Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Central Nervous System
  4. Back
  5. Multiple Sclerosis
  6. Siponimod for Secondary Progressive Multiple Sclerosis (920)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Siponimod for Secondary Progressive Multiple Sclerosis (920)

Siponimod (Mayzent®) is accepted for use within NHS Scotland for the treatment of adult
patients with secondary progressive multiple sclerosis (SPMS) with active disease
evidenced by relapses (in the past 1 year) and / or imaging features of inflammatory
activity. This will be defined as new T2 lesions / contrasting enhancement / enlarging T2
lesion on MRI scan (at least one lesion within 1 year).

In a randomised, double-blind, placebo-controlled phase III study, siponimod was
associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. Siponimod reduced the risk of 6-month confirmed disability progression by 26% compared to placebo.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 31/07/2024

Next review date: 30/06/2027

Author(s): Pushkar Shah.

Version: 2

Author email(s): pushkar.shah@ggc.scot.nhs.uk.

Approved By: Medicines Utilisation Subcommittee of ADTC

Reviewer name(s): Pushkar Shah.

Document Id: 920